Video

WCLC Updates in Immunotherapy for NSCLC

Author(s):

Stephen Liu, MD, Georgetown Lombardi Comprehensive Cancer CenterSarah Goldberg, MD, MPH, Yale School of Medicine

Key opinion leaders discuss recent trial data on the clinical efficacy of immunotherapy for the treatment of non–small cell lung cancer (NSCLC).

Data from the following clinical trials are discussed:

  • OA01.06 - Randomized Phase 2 Study of Nivolumab (N) Versus Nivolumab and Ipilimumab (NI) Combination in EGFR-Mutant NSCLC
  • PS01.09 - Pembrolizumab Plus Ipilimumab vs Pembrolizumab Plus Placebo as 1L Therapy for Metastatic NSCLC of PD-L1 TPS ≥50%: KEYNOTE-598
  • OA01.03- Clinical Benefits of First-line (1L) Cemiplimab Monotherapy by PD-L1 Expression Levels in Patients With Advanced NSCLC
Related Videos
Zofia Piotrowska, MD, MHS, and Martin Dietrich, MD, PhD, experts on lung cancer
Zofia Piotrowska, MD, MHS, and Martin Dietrich, MD, PhD, experts on lung cancer
David R. Spigel, MD, chief scientific officer, Sarah Cannon Research Institute
Video 6 - "Reflex Testing for Patients with Suspected Lung Cancer"
Video 5 "Biomarker Testing in Early-Stage NSCLC"
Suresh Ramalingam, MD, and Chandler Park, MD
Suresh S. Ramalingam, MD, FACP, FASCO, professor, Department of Hematology and Medical Oncology, Roberto C. Goizueta Distinguished Chair for Cancer Research, Emory University School of Medicine, executive director, Winship Cancer Institute of Emory University, associate vice president, cancer, Woodruff Health Sciences Center
Byoung Chol Cho, MD, PhD, professor, internal medicine, Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine
Ben Levy, MD, and Yan Leyfman, MD
BDTX-1535 – A MasterKey EGFR Inhibitor Targeting Classical, Non-Classical, and the C797S Resistance Mutation To Address The Evolved Landscape Of EGFR Mutant NSCLC
Related Content
Fabrice Barlesi, MD, PhD
June 10th 2024

Adjuvant Alectinib Approved in Europe for ALK+ Early-Stage NSCLC

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

Minesh Mehta, MD
June 4th 2024

TTFields Plus BSC Prolongs Time to Intracranial Progression in NSCLC Brain Metastases

Hari B. Keshava, MD
October 23rd 2023

Keshava Emphasizes the Importance of Lung Nodule Programs for Early Lung Cancer Detection

David Planchard, MD, PhD
June 4th 2024

Osimertinib Plus Chemotherapy Moves One Step Closer to EU Approval in EGFR+ Advanced NSCLC

Tina Cascone, MD, PhD, of The University of Texas MD Anderson Cancer Center
June 3rd 2024

Perioperative Nivolumab Regimen Improves EFS, Resection Rates in Stage III N2/non-N2 NSCLC